Literature DB >> 20890201

Functional outcome after convulsive status epilepticus.

Stéphane Legriel1, Elie Azoulay, Matthieu Resche-Rigon, Virginie Lemiale, Bruno Mourvillier, Achille Kouatchet, Gilles Troché, Manuel Wolf, Richard Galliot, Géraldine Dessertaine, Danièle Combaux, Frederic Jacobs, Pascal Beuret, Bruno Megarbane, Pierre Carli, Yves Lambert, Fabrice Bruneel, Jean-Pierre Bedos.   

Abstract

OBJECTIVES: Few outcome data are available about convulsive status epilepticus managed in the intensive care unit. We studied 90-day functional outcomes and their determinants in patients with convulsive status epilepticus.
DESIGN: Two hundred forty-eight convulsive status epilepticus patients admitted to 18 intensive care units in 2005-2007 were included in a prospective observational cohort study. The main outcome measure was a Glasgow Outcome Scale score of 5 (good recovery) on day 90. MAIN
RESULTS: Convulsive status epilepticus occurred out of hospital in 177 (67%) patients, and all but 15 patients were still seizing at medical team arrival. The median time from convulsive status epilepticus onset to anticonvulsant drug initiation was 40 mins (interquartile range, 5-80). Total seizure duration was 85 mins (interquartile range, 46.5-180). Convulsive status epilepticus was refractory in 49 (20%) patients. The most common causes of convulsive status epilepticus were anticonvulsive agent withdrawal (36.4%) in patients with previous epilepsy and stroke (27.7%) in inaugural convulsive status epilepticus. Mechanical ventilation was needed in 210 (85%) patients. On day 90, 42 (18.8%) patients were dead, 87 (38.8%) had marked functional impairments (Glasgow Outcome Scale score, 2-4), and 95 (42.4%) had a good recovery (Glasgow Outcome Scale score, 5). Factors showing independent positive associations with poor outcome (Glasgow Outcome Scale score, <5) were older age (odds ratio, 1.04/year; 95% confidence interval, 1.02-1.05; p=.0005), cerebral insult (odds ratio, 2.70; 95% confidence interval, 1.37-5.26; p=.007), longer seizure duration (odds ratio, 1.72/120 min; 95% confidence interval, 1.05-2.86; p=.03), on-scene focal neurologic signs (odds ratio, 2.08; 95% confidence interval, 1.03-4.16; p=.04), and refractory convulsive status epilepticus (odds ratio, 2.70; 95% confidence interval, 1.02-7.14; p=.045).
CONCLUSIONS: Ninety days after intensive care unit admission for convulsive status epilepticus, half the survivors had severe functional impairments. Longer seizure duration, cerebral insult, and refractory convulsive status epilepticus were strongly associated with poor outcomes, suggesting a role for early neuroprotective strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890201     DOI: 10.1097/CCM.0b013e3181f859a6

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  28 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

Review 2.  Treatment of drug-induced seizures.

Authors:  Hsien-Yi Chen; Timothy E Albertson; Kent R Olson
Journal:  Br J Clin Pharmacol       Date:  2015-09-17       Impact factor: 4.335

3.  A rare cause of status epilepticus.

Authors:  Stephane Legriel; Sybille Merceron; Fernando Pico; Yves-Sebastien Cordoliani; Jean-Pierre Bedos
Journal:  Intensive Care Med       Date:  2011-07-14       Impact factor: 17.440

4.  Emergency Neurological Life Support: Status Epilepticus.

Authors:  Jan Claassen; Joshua N Goldstein
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 5.  Emergency Neurological Life Support: Status Epilepticus.

Authors:  Jan Claassen; James J Riviello; Robert Silbergleit
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

6.  Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.

Authors:  Annalena Hottinger; Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

7.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

8.  Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus.

Authors:  Christopher R Newey; Dolora Wisco; Premkumar Nattanmai; Aarti Sarwal
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

9.  Relationship between cortex and pulvinar abnormalities on diffusion-weighted imaging in status epilepticus.

Authors:  Yoshiharu Nakae; Yosuke Kudo; Ryoo Yamamoto; Yuichi Dobashi; Yuichi Kawabata; Shingo Ikeda; Mutsumi Yokoyama; Yuichi Higashiyama; Hiroshi Doi; Ken Johkura; Fumiaki Tanaka
Journal:  J Neurol       Date:  2015-11-03       Impact factor: 4.849

Review 10.  Emergency neurological life support: status epilepticus.

Authors:  Jan Claassen; Robert Silbergleit; Scott D Weingart; Wade S Smith
Journal:  Neurocrit Care       Date:  2012-09       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.